Molecular analysis is very important in CLB‐AML with APL‐like phenotype in terms of predicting prognosis and determining the optimal treatment strategy including allogeneic stem cell transplantation or molecular targeted therapies such as FLT3 or IDH1/2 inhibitors. The gene discussed is FLT3; the disease is acute myeloid leukemia.